ACTR-48. FEASIBILITY OF DISCONTINUATION OF ADJUVANT TEMOZOLOMIDE AFTER 12 CYCLES REMAINING WITHOUT PROGRESSION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

BACKGROUND: Standard of care for newly diagnosed glioblastoma (GBM) has been chemoradiotherapy with concomitant and adjuvant temozolomide (TMZ) (Stupp regimen). Optimal number of adjuvant TMZ cycles, however, has not been well established yet, although the pivotal trial used 6 cycles. In routine pra...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Nagane, Motoo, Kobayashi, Keiichi, Saito, Kuniaki, Shimizu, Saki, Suematsu, Shinya, Kume, Satoshi, Okamura, Yuma, Shiokawa, Yoshiaki
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216401/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.080
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky